Clinical response in the overall series and according to treatment received
| All patients n (%) | Platinum-based n (%) | PLD/trabectedin n (%) | P value | |
| All cases | 52 | 26 | 26 | NS |
| Complete response (CR) Partial response (PR) Stable disease (SD) Clinical benefit (CR+PR+SD) Progression | 3 (6%) 9 (17%) 20 (38%) 32 (62%) 20 (38%) | 3 (11.5%) 4 (15%) 10 (38%) 17 (65%) 9 (35%) | 0 5 (19%) 10 (38%) 15 (57%) 11 (42%) | NS NS NS NS NS |
PLD, pegylated liposomal doxorubicin.